
-
EU was born to 'screw' US, Trump says
-
Trump's trade envoy Jamieson Greer confirmed by lawmakers
-
Eyeing Trump trade policy shakeup, Eli Lilly to build 4 US factories
-
Amazon's next-gen Alexa gets AI upgrade
-
G20 leaders say global stability threatened by declining cooperation
-
US new home sales miss expectations in January on cold weather
-
EU vows to slash red tape but stick to climate goals
-
France court orders retrial of Chilean over alleged murder of ex-girlfriend
-
Dreadlocks and downward dogs: Oslo's new bishop takes unorthodox approach
-
Indonesia agrees deal with Apple that could end iPhone sales ban
-
Global stability threatened by backslide in cooperation: S.Africa
-
'Sorry I couldn't protect you': Israel mourns Bibas mother, sons
-
BP ditches climate targets in pivot back to oil and gas
-
EU seeks to balance business needs, climate goals
-
Stock markets rally with tech in focus
-
BP to up oil and gas output, slash clean energy spend in overhaul
-
Los Angeles wildfires costliest in history: Munich Re
-
'Brat' icon Charli XCX picks up Brit award for best songwriter
-
AB InBev posts record sales in 2024 despite beer volumes slipping
-
Aston Martin cuts jobs as weak China demand weighs
-
Stellantis says 2024 profits fall 70% on N. America troubles
-
'Joyful' South Koreans hope rising births will continue
-
Indonesia agrees deal with Apple that could end iPhone sales ban: reports
-
US says Gaza ceasefire talks on track
-
Tech surge helps Hong Kong lead most Asian markets higher
-
Hong Kong to slash public spending, build AI institute
-
Israelis mass for funeral of Bibas hostages killed in Gaza
-
Most Asian markets rebound as Hong Kong tech rally resumes
-
Under pressure, EU to take axe to green rules
-
Shunned by US, Europe courts India over trade and security
-
BP to unveil strategy shakeup amid energy transition
-
Private US company set for second Moon landing attempt
-
New cocktails shake up Oscar night
-
Leading rare earths miner sees profits fall as prices sag
-
Tesla sinks below $1 tn market value as European auto sales slump
-
Paint them white: how Brazil is keeping trains on track
-
Japan's ANA to purchase mega-order of 77 new jets
-
US hardens visa sanctions over Cuba medical program
-
'A normal family', says son of surgeon in French sex abuse trial
-
Stocks slide as US consumer confidence tumbles, tech slumps
-
Germany's next leader grapples to boost defence spending
-
Stock markets shrug off Trump trade war fears but tech sags
-
UK PM pledges to spend 2.5 percent of GDP on defence by 2027
-
'Matter of survival': Nations spar over nature funding at UN talks
-
German family-run machine maker issues SOS to future government
-
Stock markets struggle on fears over Trump's China tech curbs
-
Indonesia agrees to terms with Apple to lift iPhone sales ban: source
-
Chance huge asteroid will hit Earth down to 0.001 percent
-
Unilever boss to step down after less than two years at helm
-
Kate Bush leads UK musicians in 'silent album' AI fight

Eyeing Trump trade policy shakeup, Eli Lilly to build 4 US factories
US pharmaceutical giant Eli Lilly announced Wednesday that it will build four additional new manufacturing sites in the United States in a committment designed to influence upcoming Trump administration decisions on trade and other issues.
The drugmaker, which is in growth mode thanks partly to the success of anti-obesity drugs Zepbound and Mounjaro, expects to add more than 3,000 jobs at the four sites as it committed to tens of billions of dollars in additional investment.
Chief Executive David Ricks said in a statement the boosted capital spending underscores the company's "optimism about the potential of our pipeline" and determination to "stay ahead of anticipated demand for safe, high-quality, FDA-approved medicines of the future."
The move, announced at a Washington news conference, comes as Trump proceeds with a deluge of tariff actions and proposed tax cut extensions designed to incentivize global companies to invest in the United States. Trump's administration is also undertaking deep job cuts across the US regulatory universe that could affect such processes as the application for new drugs.
The company's press release described Trump's 2017 corporate tax cut as "foundational to Lilly's domestic manufacturing investments," adding that "it is essential that these policies are extended this year."
In an interview with CNBC, Ricks said he would call on the Trump administration to address lengthy permitting times to build new facilities due to onerous requirements of the US Food and Drug Administration.
Ricks also aims to influence the "contours" of Trump's trade policy, saying "it makes no sense to punish companies that are pursuing this agenda with the administration and on behalf of the American people."
Wednesday's announcement will raise Lilly's domestic capital expansion commitment to $50 billion from $23 billion previously committed between 2020 and 2024 to construct or expand sites in the states of North Carolina, Indiana and Wisconsin.
The company is "currently in negotiations with several states and welcomes additional interest by March 12, 2025," said a press release that included a link to express interest online.
Shares of Lilly rose 1.7 percent shortly after midday.
H.Meyer--CPN